JW Pharmaceutical said April 9 it signed an exclusive licensing agreement with China’s Gan & Lee Pharmaceuticals to bring in bofanglutide (development code GZR18), a glucagon-like peptide-1 (GLP-1) receptor agonist drug candidate.
Under the deal, JW Pharmaceutical secured exclusive rights in South Korea covering development, regulatory approval, marketing and commercialization. The total contract value is $81.10 million (about 110 billion won), with sales-based royalties to be paid separately.
The agreement also includes rights for four indications: Type 2 diabetes, obesity, obstructive sleep apnea (OSA) and metabolic dysfunction-associated steatohepatitis (MASH).
Bofanglutide is a synthetic peptide being developed as a subcutaneous injection given once every two weeks. The company said it works by stimulating insulin secretion and slowing gastric emptying to help maintain satiety, reducing appetite and body weight. In a Phase 2a trial, average body weight fell 17.29% after 30 weeks of dosing every two weeks.
JW Pharmaceutical plans to launch Phase 3 trials in South Korea in the second half of this year for obesity and Type 2 diabetes at the same time. CEO Shin Young-seop said, “Based on our proven development capabilities, we will successfully advance the commercialization of bofanglutide in Korea and provide patients with metabolic diseases an innovative treatment option.”
Under the deal, JW Pharmaceutical secured exclusive rights in South Korea covering development, regulatory approval, marketing and commercialization. The total contract value is $81.10 million (about 110 billion won), with sales-based royalties to be paid separately.
The agreement also includes rights for four indications: Type 2 diabetes, obesity, obstructive sleep apnea (OSA) and metabolic dysfunction-associated steatohepatitis (MASH).
Bofanglutide is a synthetic peptide being developed as a subcutaneous injection given once every two weeks. The company said it works by stimulating insulin secretion and slowing gastric emptying to help maintain satiety, reducing appetite and body weight. In a Phase 2a trial, average body weight fell 17.29% after 30 weeks of dosing every two weeks.
JW Pharmaceutical plans to launch Phase 3 trials in South Korea in the second half of this year for obesity and Type 2 diabetes at the same time. CEO Shin Young-seop said, “Based on our proven development capabilities, we will successfully advance the commercialization of bofanglutide in Korea and provide patients with metabolic diseases an innovative treatment option.”
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.